The CREM-IL-15 axis: decoding the persistence-exhaustion paradox in NK cell immunotherapy [0.03%]
CREM-IL-15轴：破解NK细胞免疫治疗中持久性与耗竭悖论的机制
Amr Ali Mohamed Abdelgawwad El-Sehrawy,Mutaz Jamal Al-Khreisat,Jalpa R Patel et al.
Amr Ali Mohamed Abdelgawwad El-Sehrawy et al.
Natural killer (NK) cells are critical components of the innate immune system, renowned for their ability to recognize and eliminate malignant and infected cells without prior sensitization. NK cell immunotherapy encompasses various approac...
Correction: Immunological impact of tumor-draining lymph node dissection on systemic Th1-like CD4+ T cells in patients with early-stage lung cancer [0.03%]
早期肺癌患者肿瘤引流淋巴结清扫对系统性Th1型CD4+T细胞免疫影响的更正通知
Atsushi Kamigaichi,Hiroshi Kagamu,Yoshihiro Miyata et al.
Atsushi Kamigaichi et al.
Published Erratum
Cancer immunology, immunotherapy : CII. 2026 Aug 1;75(8):197. DOI:10.1007/s00262-026-04490-0 2026
Dual inhibition of tumor cells and tumor-associated neutrophils by anti-CXCR2 antibodies suppresses tumor growth and augments immunotherapy efficacy in ARID1A-deficient pancreatic cancer [0.03%]
抗CXCR2抗体双重抑制肿瘤细胞和肿瘤相关中性粒细胞，可抑制ARID1A缺乏型胰腺癌的发展并增强免疫治疗的疗效
Tzu-Lei Kuo,Kuan-Chung Hsiao,Ko-Jiunn Liu et al.
Tzu-Lei Kuo et al.
Pancreatic ductal adenocarcinoma (PDAC) is largely resistant to immune checkpoint blockade (ICB) due to its highly immunosuppressive tumor microenvironment. How to switch the "immune-cold" microenvironment to "immune hot" one is a clinical ...
Therapeutic targeting of CD47 using a tri-specific NK cell engager to inhibit multiple myeloma [0.03%]
靶向CD47的三特异性NK细胞衔接剂抑制多发性骨髓瘤的治疗作用
Ratchaneewan Sumankan,Prin Sungwan,Natthanich Boonsatit et al.
Ratchaneewan Sumankan et al.
Multiple myeloma (MM), a hematological malignancy, remains an incurable disease due to the development of resistance to the treatment; thus, there is an urgent need for new and effective therapeutic strategies, particularly for patients who...
Dekun Song,Guorong Yan,Guolong Zhang
Dekun Song
Mast cells (MCs) are tissue-resident immune cells that accumulate in the tumor microenvironment (TME) and display marked functional plasticity. Rather than acting through fixed pro-tumor or anti-tumor phenotypes, tumor-associated MCs acquir...
Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma [0.03%]
靶向ESCC的诱导多能干细胞来源的MUC1-CAR-NK细胞的疗效研究
Yuting Peng,Tian Guan,Yi Xiao et al.
Yuting Peng et al.
Background: MUC1 is frequently overexpressed in esophageal squamous cell carcinoma (ESCC), but MUC1-targeted CAR-NK cells remain unexplored in this malignancy. ...
HBO1 suppresses anti-tumor immunity of CD8⁺ T Cells in thyroid cancer by recruiting BRD4 to regulate VTCN1 expression [0.03%]
HBO1通过募集BRD4调节VTCN1表达从而抑制甲状腺癌中CD8⁺T细胞的抗肿瘤免疫作用
Yan Chen,Feng Zeng,Shan Liao et al.
Yan Chen et al.
Thyroid cancer is the most common endocrine malignancy. Although surgery remains the primary treatment, advanced disease frequently recurs or metastasizes, and subsequent therapies yield suboptimal outcomes. Immunotherapy holds promise, yet...
Adjuvant immunotherapy in high-risk stage II melanoma: real-world outcomes from a large multicenter retrospective study [0.03%]
高危II期黑色素瘤辅助免疫治疗的真实世界研究结局：一项大规模多中心回顾性研究
Vincenzo De Falco,Antonino Colloca,Giuseppe Argenziano et al.
Vincenzo De Falco et al.
Background: Cutaneous melanoma (CM) is an aggressive cancer since early stages. Stage IIB/C CM present significant recurrence risk. Recently, adjuvant immunotherapy demonstrated to increase recurrence-free survival (RFS) ...
Pilot report of an anti-PD-1/VEGF bispecific antibody for treating recurrent H3K27M-mutant diffuse midline gliomas [0.03%]
抗PD-1/VEGF双特异性抗体治疗复发H3K27M突变弥漫内生性桥脑胶质瘤的病例报告
Li Yanchu,Wang Hongbin,Yuan Xiaoli et al.
Li Yanchu et al.
Background: H3K27M-mutant diffuse midline gliomas (DMGs) are highly aggressive, immunosuppressive tumors that are resistant to conventional therapies. Median overall survival is typically 8-11 months after diagnosis; fewe...
Survival outcomes of conversion curative therapy following atezolizumab-bevacizumab in advanced hepatocellular carcinoma [0.03%]
阿特朱单抗联合贝伐珠单抗转换治疗在晚期肝细胞癌患者中的生存预后研究
Ying-Hsin Chen,Wei-Feng Li,Yen-Hao Chen et al.
Ying-Hsin Chen et al.
Background: The prognostic value of curative therapies-including liver transplantation, hepatectomy, and local ablation-in patients with advanced hepatocellular carcinoma (HCC) following atezolizumab plus bevacizumab trea...